Pure Health Holding PJSC

Pure Health Holding PJSC has a debt-to-equity ratio of 1.0, indicating a balanced capital structure where debt and equity are equally weighted. The company's liquidity is assessed as medium, with a current ratio of 1.35, suggesting it can cover its short-term liabilities but with limited surplus. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, the company's return on equity (ROE) is 10.94%, which is a strong indicator of efficient use of shareholders' equity. The return on assets (ROA) is 3.5%, which is in line with industry expectations for healthcare facilities and services. These metrics suggest that the company is generating reasonable returns relative to its asset base and equity. The company's revenue is primarily concentrated in the pharmaceuticals and healthcare services segments, with no specific geographic breakdown provided in the available data. This concentration may expose the company to risks associated with regulatory changes or market shifts in the healthcare sector. Looking at the growth trajectory, the company's operating cash flow of 4.93 billion AED and free cash flow of 2.36 billion AED indicate a strong cash generation capability. However, the capital expenditure of -1.12 billion AED suggests that the company is investing in its operations, which could support future growth. The outlook for the current fiscal year and the next fiscal year is not explicitly provided, but the company's cash flow metrics suggest a stable financial position. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's debt levels are balanced with equity, and there is no immediate threat of dilution. However, the negative net cash position after subtracting total debt is a key flag that could impact liquidity in the short term. Recent events and filings do not provide specific details, but the company's financial performance and analyst estimates suggest a stable outlook. The mean price target of 3.81 AED and the median price target of 3.83 AED indicate a generally positive sentiment among analysts, with a mean recommendation of 1.83, which is close to a strong buy rating.